Adenoid Cystic Carcinoma - 45 Studies Found
| Completed |
: Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma : Adenoid Cystic Carcinoma : 2017-03-13 :
|
| Completed |
: Study of RAD001 in Adenoid Cystic Carcinoma : Adenoid Cystic Carcinoma : 2010-05-31 : Drug: RAD001 RAD001 10 mg po daily medication |
| Completed |
: Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Adenoid Cystic Carcinoma of the Head and Neck : Adenoid Cystic Carcinoma : 2007-12-19 : Drug: doxorubicin and bortezomib Patients will be treated with bortezomib 1.3 mg/m2, intravenously on da |
| Completed |
: Adenoid Cystic Carcinoma, Erbitux, and Particle Therapy : Adenoid Cystic Carcinoma : 2010-08-30 : Drug: Cetuximab cetuximab initial dose (7 days prior to RT treatment start): 400 mg/m² body surface |
| Completed |
: Dovitinib in Adenoid Cystic Carcinoma : Adenoid Cystic Carcinoma : 2011-08-09 : Drug: TKI258 (Dovitinib): TKI258 (Dovitinib): 500 mg daily po medication with 5 days on/2 days off sched |
| Completed |
: Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma : Adenoid Cystic Carcinoma : 2016-05-19 : Drug: Lenvatinib |
| Completed |
: Study of Dovitinib (TKI258) in Adenoid Cystic Carcinoma : Adenoid Cystic Carcinoma : 2012-01-17 : Drug: Dovitinib (TKI258) 500 mg orally on a 5-days on/2-days off schedule each week of a 4-week (28-day) |
| Completed |
: Compassionate Use of Brontictuzumab for Adenoid Cystic Carcinoma (ACC) : Adenoid Cystic Carcinoma : 2016-01-22 : Drug: Brontictuzumab 1.5 mg/Kg intravenously every three weeks. |
| Active, not recruiting |
: Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma : Adenoid Cystic Carcinoma : 2014-03-24 : Drug: Regorafenib All eligible patients will receive a starting regorafenib dose of 120 mg daily taken o |
| Completed |
: Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma : Adenoid Cystic Carcinoma : 2012-03-16 : Drug: AG-013736 (AXITINIB) All eligible patients will receive a starting axitinib dose of 5 mg twice dai |